Product Description
Brinzolamide ophthalmic (eye) drops is used to treat increased pressure in the eye caused by open-angle glaucoma or a condition called ocular hypertension. Both eye conditions are caused by high pressure in your eye and can lead to pain from pressure in your eye and then can eventually harm your vision. This medicine can help you keep your sight by reducing the pressure in your eye and stopping eye pain. (Sourced from: https://www.mayoclinic.org/drugs-supplements/brinzolamide-ophthalmic-route/description/drg-20062342)
Mechanisms of Action: CA Inhibitor
Novel Mechanism: No
Modality: Small Molecule
Route of Administration: Topical, Ophthalmic
FDA Designation: *
Approval Status: Approved
Approved Countries: Algeria | Argentina | Australia | Austria | Bangladesh | Belgium | Bosnia | Brazil | Bulgaria | Canada | Chile | Colombia | Croatia | Cyprus | Czech | Denmark | Dominican Republic | Ecuador | Egypt | Estonia | European Medicines Agency | Finland | France | Germany | Greece | Hong Kong | Hungary | Iceland | India | Indonesia | Ireland | Israel | Italy | Japan | Jordan | Korea | Latvia | Lebanon | Lithuania | Luxembourg | Malaysia | Malta | Mexico | Morocco | Netherlands | New Zealand | Norway | Pakistan | Peru | Philippines | Poland | Portugal | Romania | Russia | Saudi Arabia | Serbia | Singapore | Slovakia | Slovenia | South Africa | Spain | Sri Lanka | Sweden | Switzerland | Taiwan | Thailand | Tunisia | Turkey | Ukraine | United Arab Emirates | United Kingdom | United States | Uruguay | Venezuela | Vietnam
Approved Indications: None
Known Adverse Events: None
Company: Alcon
Company Location: Europe
Company Founding Year: 1945
Additional Commercial Interests: None
Clinical Description
Countries in Clinic: Greece
Active Clinical Trial Count: 2
Recent & Upcoming Milestones
Highest Development Phases
Phase 3: Glaucoma|Hypertension
Trial ID |
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
Latest Trial Update Date |
Data Updated |
|---|---|---|---|---|---|---|---|---|
2023-506494-35-00 |
BECRO/OV/BRINZOTIM | P3 |
Active, not recruiting |
Hypertension|Glaucoma |
2025-06-30 |
2025-05-02 |
Treatments |
|
2022-002524-12 |
2022-002524-12 | P3 |
Active, not recruiting |
Glaucoma|Hypertension |
2024-01-29 |
Recent News Events
Date |
Type |
Title |
|---|---|---|
|
12/08/2025 |
News Article |
North Shore Appoints Experienced Mining Executive to the Board |
|
09/24/2025 |
News Article |
Azarga Metals NI 43-101 Technical Report Filed for the Marg Project, Central Yukon |
|
09/08/2025 |
News Article |
Azarga Metals Announces Mineral Resource Estimate for the Marg Project, Central Yukon |
|
09/08/2025 |
News Article |
Canadian Investment Regulatory Organization Trade Resumption - AZR |